Historical Valuation
Monte Rosa Therapeutics Inc (GLUE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29.49 is considered Overvalued compared with the five-year average of -4.79. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 4.14 to 15.99 according to relative valuation methord. Compared to the current price of 24.28 USD , Monte Rosa Therapeutics Inc is Overvalued By 51.88%.
Relative Value
Fair Zone
4.14-15.99
Current Price：24.28
51.88%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Monte Rosa Therapeutics Inc (GLUE) has a current Price-to-Book (P/B) ratio of 3.85. Compared to its 3-year average P/B ratio of 1.64 , the current P/B ratio is approximately 134.61% higher. Relative to its 5-year average P/B ratio of 1.78, the current P/B ratio is about 116.77% higher. Monte Rosa Therapeutics Inc (GLUE) has a Forward Free Cash Flow (FCF) yield of approximately 14.55%. Compared to its 3-year average FCF yield of -19.02%, the current FCF yield is approximately -176.48% lower. Relative to its 5-year average FCF yield of -17.36% , the current FCF yield is about -183.81% lower.
P/B
Median3y
1.64
Median5y
1.78
FCF Yield
Median3y
-19.02
Median5y
-17.36
Competitors Valuation Multiple
AI Analysis for GLUE
The average P/S ratio for GLUE competitors is 10.60, providing a benchmark for relative valuation. Monte Rosa Therapeutics Inc Corp (GLUE.O) exhibits a P/S ratio of 29.49, which is 178.13% above the industry average. Given its robust revenue growth of 38.54%, this premium appears sustainable.
Performance Decomposition
AI Analysis for GLUE
1Y
3Y
5Y
Market capitalization of GLUE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GLUE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GLUE currently overvalued or undervalued?
Monte Rosa Therapeutics Inc (GLUE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29.49 is considered Overvalued compared with the five-year average of -4.79. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 4.14 to 15.99 according to relative valuation methord. Compared to the current price of 24.28 USD , Monte Rosa Therapeutics Inc is Overvalued By 51.88% .
What is Monte Rosa Therapeutics Inc (GLUE) fair value?
GLUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 4.14 to 15.99 according to relative valuation methord.
How does GLUE's valuation metrics compare to the industry average?
The average P/S ratio for GLUE's competitors is 10.60, providing a benchmark for relative valuation. Monte Rosa Therapeutics Inc Corp (GLUE) exhibits a P/S ratio of 29.49, which is 178.13% above the industry average. Given its robust revenue growth of 38.54%, this premium appears sustainable.
What is the current P/B ratio for Monte Rosa Therapeutics Inc (GLUE) as of Jan 10 2026?
As of Jan 10 2026, Monte Rosa Therapeutics Inc (GLUE) has a P/B ratio of 3.85. This indicates that the market values GLUE at 3.85 times its book value.
What is the current FCF Yield for Monte Rosa Therapeutics Inc (GLUE) as of Jan 10 2026?
As of Jan 10 2026, Monte Rosa Therapeutics Inc (GLUE) has a FCF Yield of 14.55%. This means that for every dollar of Monte Rosa Therapeutics Inc’s market capitalization, the company generates 14.55 cents in free cash flow.
What is the current Forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE) as of Jan 10 2026?
As of Jan 10 2026, Monte Rosa Therapeutics Inc (GLUE) has a Forward P/E ratio of -8.89. This means the market is willing to pay $-8.89 for every dollar of Monte Rosa Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Monte Rosa Therapeutics Inc (GLUE) as of Jan 10 2026?
As of Jan 10 2026, Monte Rosa Therapeutics Inc (GLUE) has a Forward P/S ratio of 29.49. This means the market is valuing GLUE at $29.49 for every dollar of expected revenue over the next 12 months.